Quintiles Unveils Its New E-Commerce Products--But Where's WebMD?

If ever an industry needed to find new ways of marketing itself, the currently floundering CRO business certainly fills the bill. A number of industry observers and insiders argue that Internet technologies could play a crucial rule in transforming R&D outsourcing from its role as a temporary means of boosting capacity to that of drug development partners. Each of the top three CROs have, in fact, devoted significant resources to building Internet capabilities. But the most publicized and ambitious such effort from Quintiles Transnational Corp., which is attempting to leverage its substantial financial resources, as well as the advantages of having a major commercialization outsourcing business that complements its drug development operations, to create an Internet platform whose scope the competition simply cannot match.

If ever an industry needed to find new ways of marketing itself, the currently floundering CRO business certainly fills the bill. A downturn that at first might have been shrugged off as a temporary slump resulting from a combination of major contract cancellations and a general slowdown in Big Pharma business due to the disruptive effects of drug company consolidation, increasingly seems to raise more fundamental questions about the continued viability of the CRO business model. In particular, CROs, once viewed as a way to tap into the profit-rich pharmaceutical industry without assuming all of the risks associated with drug development, now appear susceptible to the same sorts of hazards, without the same upsides, as their customers.

For years, and with increased urgency as of late, CRO executives have spoken of building deeper and longer term strategic...

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.